BACKGROUND AND PURPOSE: The purpose of this study was to compare escitalopram, problem-solving therapy, and placebo to prevent poststroke depression during 6 months after discontinuation of treatment. METHODS: We examined for depression 33 patients assigned to placebo, 34 to escitalopram, and 41 to problem-solving therapy. RESULTS: After controlling for age, gender, prior mood disorder, and severity of stroke, new-onset major depression and Hamilton Depression scores were significantly higher 6 months after escitalopram was discontinued compared with the problem-solving therapy or placebo groups. CONCLUSIONS: Discontinuation of escitalopram may increase poststroke depressive symptoms.
RCT Entities:
BACKGROUND AND PURPOSE: The purpose of this study was to compare escitalopram, problem-solving therapy, and placebo to prevent poststroke depression during 6 months after discontinuation of treatment. METHODS: We examined for depression 33 patients assigned to placebo, 34 to escitalopram, and 41 to problem-solving therapy. RESULTS: After controlling for age, gender, prior mood disorder, and severity of stroke, new-onset major depression and Hamilton Depression scores were significantly higher 6 months after escitalopram was discontinued compared with the problem-solving therapy or placebo groups. CONCLUSIONS: Discontinuation of escitalopram may increase poststroke depressive symptoms.
Authors: Katsunaka Mikami; Ricardo E Jorge; Harold P Adams; Patricia H Davis; Enrique C Leira; Mijin Jang; Robert G Robinson Journal: Am J Geriatr Psychiatry Date: 2011-12 Impact factor: 4.105
Authors: Robert G Robinson; Ricardo E Jorge; David J Moser; Laura Acion; Ana Solodkin; Steven L Small; Pasquale Fonzetti; Mark Hegel; Stephan Arndt Journal: JAMA Date: 2008-05-28 Impact factor: 56.272
Authors: Laura A Stein; Emily Goldmann; Ahmad Zamzam; Jean M Luciano; Steven R Messé; Brett L Cucchiara; Scott E Kasner; Michael T Mullen Journal: Front Neurol Date: 2018-11-02 Impact factor: 4.003